Difference between revisions of "CH Basel Balavenkatraman KK"
From Bioblast
Nirschl Lisa (talk | contribs) |
Nirschl Lisa (talk | contribs) |
||
| Line 9: | Line 9: | ||
|Team previous=Chiesi M | |Team previous=Chiesi M | ||
|Status=O2k 2007 – | |Status=O2k 2007 – | ||
|info=[[IOC106]], [[IOC39] | |info=[[IOC106]], [[IOC39]] | ||
|Info=[http://www.oroboros.at/index.php?id=1215 CH_Basel_ChiesiM] | |Info=[http://www.oroboros.at/index.php?id=1215 CH_Basel_ChiesiM] | ||
}} | }} | ||
* Previously CH_Basel_Chiesi M | * Previously CH_Basel_Chiesi M | ||
Revision as of 09:23, 23 February 2018
CH Basel Balavenkatraman KK
| O2k-Network Lab | Investigator II (iTox-PCS) - Novartis Pharma Ltd., WKL-135.3.21 |
|---|---|
| Address | Klybeckstr 191, 4057 |
| City | Basel |
| State/Prov | |
| Country | Switzerland |
| Weblink | |
| Contact | Balavenkatraman Kamal Kumar |
| Team | Grueninger S, Weiss A |
| Team previous | Chiesi M |
| Status | O2k 2007 – |
| Oroboros Events | IOC106, IOC39 |
| Topics |
O2k-Publications
update please
O2k-Abstracts
update please
- Previously CH_Basel_Chiesi M
